
    
      40 subjects will be included in the study. Diagnosis will be confirmed by MINI. Participants
      will be characterised using questionnaires, pain threshold, cognition, facial expression
      recording and MRI. Desvenlafaxine will be initiated at 50mg AM. At week 8 Desvenlafaxine may
      be increased to 100mg as clinically indicated. Measures will be repeated at the end of the
      study.
    
  